STATE OF IOWA DEPARTMENT OF
Health AND Human
SERVICES

Iowa Medicaid Drug Utilization Review (DUR) Commission

November 2, 2022

Location: **Teleconference** (Due to Federal PHE Declaration for the COVID-19 Pandemic)
Time: 9:30 a.m. – 1:30 p.m. CT

WebEx Meeting Link:
https://changehealthcare.webex.com/changehealthcare/j.php?MTID=m2f4de940cb66682f1c3a3474bf116b8a
Dial In: 1-844-245-7693
Meeting Number: 2536 077 4723
Meeting Password: 3uWE2aV9Bvs

Final Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of the Minutes
    b) August 2022 DUR Recommendation Letter to DHS
    c) Follow-Up from Previous Meeting(s)
3. Iowa Medicaid Pharmacy Update
4. Prevalence Report Summaries
    a) Iowa Total Care
    b) Fee-for-Service
    c) Amerigroup
    d) Comparative Summary
5. Public Comment* (Complete Speaker Conflict of Interest Disclosure Form)
    - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure. Five (5) minute maximum limit.
    - Written - Must submit written comments and a completed conflict of interest disclosure.
    - Reference complete public comment policy here.
    - **All submissions must be received no later than 4:30 p.m. CT October 26, 2022.**
    - Send to info@iadur.org ***Indicate in email if providing written or verbal comment.***
6. Retrospective DUR
    a) Data Presentation(s)
        i. LABA without ICS
    b) Proposal(s)

i. Concurrent Use of Opioids and Sedatives
ii. Underutilization of Beta-Blockers in Heart Failure

c) Commission Recommendations for Retrospective DUR Agenda Topics

7. Break (10 minutes)
8. Prior Authorization
   a) Annual Review of Prior Authorization Criteria
   b) Nebivolol (Bystolic) – Removal of Criteria - Initial Review
   c) Potassium Binders – Removal of Criteria – Initial Review
   d) Select Topical Psoriasis Agents - Initial Review
   e) Initial Days' Supply Limit Override, Benzodiazepines – Initial Review
   f) High Dose Opioids – Initial Review
   g) Sedative/Hypnotics, Non-Benzodiazepine – Second Review
   h) Vericiguat (Verquvo) – Second Review
   i) Maralixibat (Livmarli) – Second Review
   j) Alpelisib (Vijoice) – Second Review
   k) Mavacamten (Camzyos) – Second Review
   l) Dupilumab (Dupixent) – Second Review
   m) Viloxazine (Qelbree) – Second Review
   n) CNS Stimulants and Atomoxetine – Second Review
9. Miscellaneous
   a) DUR Digest Vol. 35, No. 1 – Initial Review
   b) MedWatch

      FDA Approves New Treatment Option for Patients with ALS

      FDA approves first treatment for prurigo nodularis
10. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a conflict of interest disclosure. Completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515)974-3131.

Next Meeting
February 1, 2023
Location TBD